M&A Deal Summary

Alaunos Therapeutics Acquires Baxter International - Indibulin

On November 6, 2006, Alaunos Therapeutics acquired life science company Baxter International - Indibulin from Baxter International

Acquisition Highlights
  • This is Alaunos Therapeutics’ 1st transaction in the Life Science sector.
  • This is Alaunos Therapeutics’ 1st transaction in the United States.
  • This is Alaunos Therapeutics’ 1st transaction in Illinois.

M&A Deal Summary

Date 2006-11-06
Target Baxter International - Indibulin
Sector Life Science
Buyer(s) Alaunos Therapeutics
Sellers(s) Baxter International
Deal Type Divestiture

Target

Baxter International - Indibulin

Deerfield, Illinois, United States
Baxter International, Inc. - Indibulin is a novel synthetic anti-cancer agent that targets mitosis like the taxanes.

Search 214,557 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Alaunos Therapeutics

Houston, Massachusetts, United States

Category Company
Founded 2003
Sector Life Science
Employees1
Revenue 3M USD (2022)
DESCRIPTION

Alaunos Therapeutics is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safer, more effective and scalable cell-based therapies for the treatment of cancer. Alaunos Therapeutics was founded in 2003 and is based in Houston, Texas.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Illinois M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2006 M&A 1 of 1

Seller(S) 1

SELLER

Baxter International

Deerfield, Illinois, United States

Category Company
Founded 1931
Sector Medical Products
Employees38,000
Revenue 10.6B USD (2024)
DESCRIPTION
Entrance to Baxter International's corporate headquarters in Deerfield, Illinois.
Entrance to Baxter International's corporate headquarters in Deerfield, Illinois.

Baxter International develops, manufactures and markets drugs and medical products for people with a variety of medical conditions. Baxter's operations are comprised of the BioScience and Medical Products segments. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. Baxter International was founded in 1931 and is based in Deerfield, Illinois.


DEAL STATS #
Overall 3 of 7
Sector: Life Science M&A 1 of 4
Type: Divestiture M&A Deals 3 of 6
State: Illinois M&A 1 of 4
Country: United States M&A 2 of 5
Year: 2006 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-09-02 COMPASS Services

United States

COMPASS Services is a leading provider of intravenous admixture services supplied to the hospital and alternate site pharmacies market.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-09-01 Edwards Lifesciences - Hemofiltration Product Line

Irvine, California, United States

Edwards Lifesciences Corp. - Hemofiltration Product Line includes manufacturer of medical products in US.

Buy -